May 9th 2024
“The results of the BRAVO study performed within the VA health care system showed significant decreases in the risk of recurrence and progression, as well as the potential for improved overall survival in patients who received a BLC compared to patients who received WLC only,” says Stephen B. Williams, MD, MBA, MS, FACS, FACHE.
UGN-102 treatment leads to meaningful DFS outcomes in NMIBC, regardless of prior TURBT
A post hoc analysis of the phase 3 ATLAS trial showed that UGN-102 with or without TURBT induced meaningful disease-free survival and duration of response in patients with non–muscle-invasive bladder cancer.
Novel gene therapy EG-70 nears 75% complete response rate in NMIBC
EG-70 is an experimental intravesical immunotherapy that does not involve viruses or integration. It aims to eliminate tumors by triggering coordinated innate and adaptive immune reactions specifically within the bladder.
Enzalutamide regimens increase undetectable PSA likelihood in nonmetastatic CSPC
More patients with nonmetastatic castration-sensitive prostate cancer reached an undetectable PSA level if they received enzalutamide, as a single agent or combined with leuprolide, vs if they received leuprolide alone.
Steerable ureteroscopic renal evacuation shows promise for kidney stone removal
May 4th 2024Steerable ureteroscopic renal evacuation using the CVAC Aspiration System demonstrated noninferiority vs standard ureteroscopy for kidney stone removal, according to findings from the prospective, randomized ASPIRE trial.
TAR-200 sustains impressive clinical activity in BCG-unresponsive NMIBC
Treatment with the intravesical gemcitabine delivery system TAR-200 led to complete responses in over 80% of patients with BCG-unresponsive, high-risk non–muscle-invasive bladder cancer, according to the latest results from the phase 2b SUNRISE-1 trial.